RE:RE:RE:Gilead's ADC Trodelvy comes up short in ER+/Her2- BC thank you notable for your detailed & broad research.
Indicators showing bolder & broader opportunities for Pela.
Some points, require a bit of comparison- analysis. To accomplish one needs to understand not only Onc ( Pelareorep), but the broader cancer therapy world in general.
The recent post, re the Pfizer trial failure, in- directly is a boost for Pela & ONC.
indications, Pela can do what that trial failed at.....making Onc a great option for Pfizer.
moving on.
Has been a long while since I posted a short term price prediction.
just for fun, ........l see Onc trading close to, $2. CDN or just over $1.60 on the NAS, this week.
i qualified " just for fun", because right or wrong, it makes little difference.
The real delivery will have to come from some ONC clinical progress.
bracelet, final enrolment, long over due
CAR-T , business deal, long over due
and,
The expected updates on Goblet ( GI cancer), ...multiple melanoma, & a few others.
Things have been too sleepy for too long.
My $2 prediction, supersedes any news, which could move much higher.
Some rough T.A. Indicators show $1.96 CDN as a resistance, hence my $2 prediction.
The recent ( last month) of trading has had very low volumes.
meaning on an uptick, there would be little sell- off.
visualize an old wet rag. All of the excess water , has been wrung out of onc SP.
I could come up with a dozen theories regarding the news silence.
Again, I don't know. So , wait & see.
Have a good week all.
stay healthy & safe.